SIRT6 Mitigates Heart Failure With Preserved Ejection Fraction in Diabetes

Xiaoqian Wu,Huan Liu,Alan Brooks,Suowen Xu,Jinque Luo,Rebbeca Steiner,Deanne M. Mickelsen,Christine S. Moravec,Alexis D. Jeffrey,Eric M. Small,Zheng Gen Jin
DOI: https://doi.org/10.1161/circresaha.121.318988
IF: 23.213
2022-10-25
Circulation Research
Abstract:Heart failure with preserved ejection (HFpEF) is a growing health problem without effective therapies. Epidemiological studies indicate that diabetes is a strong risk factor for HFpEF, and about 45% of patients with HFpEF are suffering from diabetes. However, the molecular mechanisms for the association of diabetes and HFpEF are poorly understood. This study was designed to explore whether the longevity gene SIRT6 (sirtuin 6) could regulate endothelial fatty acid (FA) transport and ameliorate HFpEF in diabetes. We first observed that endothelial SIRT6 expression was markedly diminished in cardiac tissues from heart failure patients with diabetes and diabetic mice with the myriad symptoms of HFpEF, which was induced by the combination of the long-term high-fat diet and one low-dose streptozocin challenge. We then generated a unique humanized SIRT6 transgenic mouse model, in which a single copy of human SIRT6 transgene was engineered at mouse Rosa26 locus and conditionally induced with the Cre-loxP technology. We found that genetically restoring endothelial SIRT6 expression in the diabetic mice ameliorated diastolic dysfunction concurrently with decreased cardiac lipid accumulation. SIRT6 gain- or loss-of-function studies showed that SIRT6 negatively regulated endothelial FA uptake. Mechanistically, SIRT6 suppressed endothelial expression of PPARγ through SIRT6-dependent deacetylation of H3K9 around PPARγ promoter region; and PPARγ downregulation mediated SIRT6-dependent inhibition of endothelial FA uptake. Importantly, oral administration of small molecule SIRT6 activator MDL-800 to diabetic mice mitigated cardiac lipid accumulation and diastolic dysfunction. The impairment of endothelial SIRT6 expression links diabetes to HFpEF through altering FA transport across the endothelial barrier. The genetic and pharmacological strategies that restore endothelial SIRT6 function in diabetes alleviated experimental HFpEF by limiting FA overtake and improving cardiac metabolism, thus warranting further clinical evaluation. Download figure Download PowerPoint
cardiac & cardiovascular systems,peripheral vascular disease,hematology
What problem does this paper attempt to address?